Qiagen signs new alliances with Pall, Polysciences

1 November 2001

Qiagen of the Netherlands has entered into an agreement with filtration,separations and purification specialist Pall Corp of the USA to jointly develop next-generation nucleic acid separation and purification products for certain applications in the life science market. The products will be marketed exclusively by the Dutch firm.

The first suite of products intended for near-term launch will focus on products combining Pall's filtration systems with Qiagen's technologies for applications in medium-, high- and ultra-high throughput separation and purification of certain types of nucleic acids analyzed in genomics applications.

In addition, the companies have entered into a long-term supply agreement for certain of Pall's existing consumables that Qiagen expects to market to its customers once slight modifications to those products are completed. Financial terms were not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.